After Adamis' COVID-19 flop, company weighs future and warns layoffs could be in the cards

Monday, the San Diego-based specialty drug maker said it kicked off a process “to explore a range of strategic and financing alternatives focused on maximizing stockholder value.” The move comes in the wake of a halt on a phase 2/3 trial of the company’s sole clinical prospect Tempol, which Adamis had been pitting against early COVID-19 in high-risk patients.